A -0.50 D prescription may look small—but it is already considered myopia.

The International Myopia Institute ( IMI ) defines myopia as a spherical-equivalent prescription of -0.50 D or more myopic when accommodation is relaxed.

But the prescription alone doesn't tell us whether your child is likely to progress.

We also want to know:

• How old is your child?

• When did the myopia begin?

• Has the prescription changed since the last examination?

• How quickly has it changed?

• Does either parent have myopia?

• How much time does your child spend outdoors?

• How much close work or screen-based activity do they do?

• Is there evidence that the eye is continuing to elongate?

• Are there other factors that increase their risk of progression?

A younger child with newly developed myopia and a history of rapid progression is a very different situation from an older child whose small prescription has remained stable.

So -0.50 D shouldn't automatically be dismissed as "too little to worry about."

A change of 0.75 D in one year is a meaningful change, particularly in a younger child.

For context, large longitudinal studies have found that progression can be substantial in school-aged children, with faster progression generally occurring at younger ages.

It doesn't mean your child's eyes are "damaged."

It also doesn't mean that a particular treatment is automatically required.

But a bigger and more useful question is:

"Why did my child's prescription change by 0.75 D, and can we slow further progression?"

A rapidly changing prescription is a reason to investigate or inquire further with a myopia management specialist.

Regular glasses are important --they correct the blurry vision caused by myopia.  But they don't specifically target the progression of myopia.

​

Myopia control glasses are designed to do both: help your child see clearly and also address myopia progression.

​

The more important question to ask yourself is:  "Whether vision correction alone is enough for my child, or whether I should also consider an approach intended to slow progression."

There isn't one answer that fits every child and family.

​

Cost is a legitimate part of the decision. In the IMI's 2025 global survey, cost to the patient remained the most frequently reported barrier to prescribing myopia interventions.

The goal isn't to convince every family to spend more money.

The goal is to make sure parents understand what they're paying for, what the potential benefit is, and what alternatives exist.

​

The benefit of myopia management is slowing the rate of progression -- not a guarantee that the prescription will stop changing.

The decision depends on your child's individual risk factors, lifestyle, and your family's budget.

Active monitoring is not the same as doing nothing.  It means keeping a close eye on your child's eye health and progression so we can make informed decisions about treatment, if and when it's needed.

​

We look at the child's current prescription and compare it with previous measurements.

If available, axial length can provide additional information about eye growth.

We then reassess whether the child appears stable or whether progression is continuing.

The IMI recommends considering factors such as age, baseline refractive error, progression rate, safety, compliance and cost when determining management strategies.

​

The important distinction:

Passive monitoring:
"Come back next year and we'll see what the prescription is."

 

Active monitoring:
"We're going to track your child's prescription and eye growth and decide together whether intervention is appropriate."

 

If your child's myopia is changing quickly, waiting another year without a plan may mean losing valuable information about the rate of progression.